Tandem Diabetes Financials
Tandem Diabetes (TNDM) reported $1.0B in revenue for fiscal year 2025, up 7.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue growth and improving gross margin are being absorbed by selling and development costs, leaving profits and cash conversion unstable.
From FY2024 to FY2025, gross profit increased by$56M while accounts receivable increased by$51M . At the same time, operating cash flow fell from$24.2M to-$9.7M , showing that better product economics were offset by slower cash collection.
The product-level margin structure improved, with gross margin rising from
Near-term liquidity still looks workable, with a current ratio of 2.5x and cash of
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Tandem Diabetes's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Tandem Diabetes has an operating margin of -18.4%, meaning the company loses $18 on every $100 of revenue. This results in a profitability score of 24/100. This is down from -10.5% the prior year.
Tandem Diabetes's revenue grew 7.9% year-over-year to $1.0B, a solid pace of expansion. This earns a growth score of 78/100.
Tandem Diabetes has a moderate D/E ratio of 2.00. This balance of debt and equity financing earns a leverage score of 31/100.
With a current ratio of 2.55, Tandem Diabetes holds $2.55 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 70/100.
Tandem Diabetes's operations used $9.7M of cash, and capex of $19.9M added to the outflow, for a free cash flow shortfall of $29.7M. This results in a cash flow score of 23/100.
Tandem Diabetes posts a -131.9% return on equity (ROE), meaning it loses $132 for every $100 of shareholders' equity. This results in a returns score of 22/100. This is down from -36.5% the prior year.
Tandem Diabetes scores 0.34, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.7B) relative to total liabilities ($725.9M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Tandem Diabetes passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Tandem Diabetes reported a net loss of $204.7M while operations used $9.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Tandem Diabetes reported an operating loss of $187.3M against $7.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Tandem Diabetes generated $1.0B in revenue in fiscal year 2025. This represents an increase of 7.9% from the prior year.
Tandem Diabetes's EBITDA was -$169.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 105.5% from the prior year.
Tandem Diabetes reported -$204.7M in net income in fiscal year 2025. This represents a decrease of 113.2% from the prior year.
Tandem Diabetes earned -$3.04 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 106.8% from the prior year.
Cash & Balance Sheet
Tandem Diabetes recorded an outflow of $29.7M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 694.1% from the prior year.
Tandem Diabetes held $90.6M in cash against $310.0M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Tandem Diabetes's gross margin was 53.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.7 percentage points from the prior year.
Tandem Diabetes's operating margin was -18.4% in fiscal year 2025, reflecting core business profitability. This is down 7.9 percentage points from the prior year.
Tandem Diabetes's net profit margin was -20.2% in fiscal year 2025, showing the share of revenue converted to profit. This is down 10.0 percentage points from the prior year.
Tandem Diabetes's ROE was -131.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 95.4 percentage points from the prior year.
Capital Allocation
Tandem Diabetes invested $193.1M in research and development in fiscal year 2025. This represents a decrease of 2.9% from the prior year.
Tandem Diabetes repurchased no shares in fiscal year 2025. This represents a decrease of 100.0% from the prior year.
Tandem Diabetes invested $19.9M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 3.7% from the prior year.
TNDM Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0B | $1.0B+7.9% | $940.2M+25.7% | $747.7M-6.7% | $801.2M+14.0% | $702.8M+40.9% | $498.8M+37.7% | $362.3M+97.0% | $183.9M+70.9% | $107.6M+27.7% | $84.2M+15.6% | $72.8M+46.5% | $49.7M+71.4% | $29.0M+1072.0% | $2.5M |
| Cost of Revenue | N/A | $468.7M+4.0% | $450.6M+18.6% | $380.0M-2.1% | $388.2M+18.9% | $326.6M+37.0% | $238.3M+41.8% | $168.1M+78.7% | $94.0M+48.1% | $63.5M+4.7% | $60.7M+31.1% | $46.3M+34.2% | $34.5M+50.9% | $22.8M+497.4% | $3.8M |
| Gross Profit | $583.3M | $546.0M+11.5% | $489.6M+33.1% | $367.7M-11.0% | $413.0M+9.8% | $376.2M+44.4% | $260.5M+34.1% | $194.2M+116.2% | $89.8M+103.7% | $44.1M+86.9% | $23.6M-11.2% | $26.6M+74.3% | $15.2M+147.3% | $6.2M+557.5% | -$1.3M |
| R&D Expenses | N/A | $193.1M-2.9% | $198.9M+17.2% | $169.7M+22.0% | $139.1M+51.1% | $92.1M+44.8% | $63.6M+40.7% | $45.2M+54.6% | $29.2M+41.5% | $20.7M+9.8% | $18.8M+10.9% | $17.0M+7.4% | $15.8M+42.5% | $11.1M+23.0% | $9.0M |
| SG&A Expenses | N/A | $445.0M+14.2% | $389.8M+10.6% | $352.5M+5.0% | $335.7M+28.4% | $261.5M+27.6% | $204.9M+23.6% | $165.7M+57.5% | $105.2M+21.8% | $86.4M+4.3% | $82.8M+5.4% | $78.6M+4.7% | $75.1M+68.7% | $44.5M+96.2% | $22.7M |
| Operating Income | -$45.8M | -$187.3M-88.9% | -$99.1M+57.5% | -$233.2M-151.2% | -$92.8M-509.9% | $22.7M+384.7% | -$8.0M+52.4% | -$16.7M+62.5% | -$44.6M+29.1% | -$62.9M+19.4% | -$78.1M-13.1% | -$69.0M+8.8% | -$75.7M-53.1% | -$49.4M-49.6% | -$33.0M |
| Interest Expense | N/A | $7.9M+6.6% | $7.4M-25.0% | $9.9M+59.2% | $6.2M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | $4.4M+6.8% | $4.2M+76.3% | $2.4M+35.3% | $1.7M+420.0% | $335K+117.6% | -$1.9M-1375.2% | $149K+192.2% | $51K+537.5% | $8K+153.3% | -$15K-250.0% | $10K-85.9% | $71K | N/A | N/A |
| Net Income | -$63.3M | -$204.7M-113.2% | -$96.0M+56.9% | -$222.6M-135.3% | -$94.6M-706.4% | $15.6M+145.4% | -$34.4M-38.9% | -$24.8M+79.8% | -$122.6M-67.9% | -$73.0M+12.5% | -$83.4M-15.2% | -$72.4M+8.9% | -$79.5M-26.0% | -$63.1M-91.2% | -$33.0M |
| EPS (Diluted) | -$0.93 | -$3.04-106.8% | -$1.47+57.1% | -$3.43-133.3% | -$1.47-712.5% | $0.24+142.9% | -$0.56-33.3% | -$0.42 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
TNDM Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $881.1M-8.9% | $967.7M+1.6% | $952.7M-9.5% | $1.1B+16.3% | $905.1M+26.3% | $716.4M+119.7% | $326.1M+58.1% | $206.3M+116.4% | $95.3M-15.2% | $112.4M-9.9% | $124.7M+17.2% | $106.5M-34.4% | $162.2M | N/A |
| Current Assets | $618.1M-14.7% | $724.5M-3.1% | $748.0M-12.0% | $850.0M+4.7% | $811.5M+27.4% | $637.2M+130.8% | $276.1M+47.0% | $187.9M+192.9% | $64.2M-30.3% | $92.1M-13.9% | $107.0M+17.9% | $90.8M-39.1% | $149.0M | N/A |
| Cash & Equivalents | $90.6M+30.9% | $69.2M+17.6% | $58.9M-65.9% | $172.5M+142.4% | $71.2M-24.8% | $94.6M+84.9% | $51.2M+22.4% | $41.8M+205.3% | $13.7M-69.3% | $44.7M+3.7% | $43.1M+38.2% | $31.2M-74.9% | $124.4M+624.7% | $17.2M |
| Inventory | $128.8M-13.9% | $149.6M-5.3% | $157.9M+42.1% | $111.1M+62.1% | $68.6M+7.6% | $63.7M+29.8% | $49.1M+146.6% | $19.9M-26.3% | $27.0M+27.4% | $21.2M+20.8% | $17.5M+47.3% | $11.9M+15.3% | $10.3M | N/A |
| Accounts Receivable | $165.5M+44.4% | $114.6M+8.6% | $105.6M-8.0% | $114.7M+3.6% | $110.7M+34.7% | $82.2M+76.4% | $46.6M+32.4% | $35.2M+69.3% | $20.8M+86.1% | $11.2M-20.5% | $14.1M+83.7% | $7.7M+44.4% | $5.3M | N/A |
| Total Liabilities | $725.9M+3.0% | $704.6M+10.3% | $639.0M+4.3% | $612.8M+29.8% | $472.0M+34.8% | $350.1M+167.0% | $131.1M+74.8% | $75.0M-39.7% | $124.5M+5.2% | $118.3M+93.2% | $61.3M+18.0% | $51.9M+11.2% | $46.7M | N/A |
| Current Liabilities | $242.7M-1.8% | $247.0M+26.5% | $195.3M+18.1% | $165.3M+25.4% | $131.9M+27.0% | $103.9M+4.5% | $99.4M+49.9% | $66.3M+83.7% | $36.1M+14.6% | $31.5M+18.7% | $26.5M+46.6% | $18.1M+23.9% | $14.6M | N/A |
| Long-Term Debt | $310.0M+0.6% | $308.3M+8.2% | $285.0M | N/A | N/A | N/A | N/A | N/A | $82.7M+2.0% | $81.1M+168.9% | $30.2M+0.5% | $30.0M | N/A | N/A |
| Total Equity | $155.2M-41.0% | $263.1M-16.1% | $313.6M-28.7% | $439.9M+1.6% | $433.1M+18.2% | $366.3M+87.9% | $195.0M+48.5% | $131.3M+550.4% | -$29.1M-391.8% | -$5.9M-109.3% | $63.5M+16.3% | $54.6M-52.8% | $115.5M+208.9% | -$106.1M |
| Retained Earnings | -$1.3B-19.5% | -$1.0B-10.1% | -$951.8M-30.5% | -$729.2M-14.9% | -$634.6M+3.7% | -$659.2M-5.5% | -$624.8M-4.1% | -$600.1M-25.6% | -$477.6M-18.1% | -$404.6M-26.0% | -$321.1M-29.1% | -$248.7M-47.0% | -$169.2M | N/A |
Not reported in any period shown, so not listed: Goodwill.
TNDM Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.5M | -$9.7M-140.1% | $24.2M+176.2% | -$31.8M-163.0% | $50.5M-54.7% | $111.4M+351.4% | $24.7M-41.1% | $41.9M+603.7% | -$8.3M+87.4% | -$66.1M-8.1% | -$61.2M-4.1% | -$58.8M+4.3% | -$61.4M-28.5% | -$47.8M-42.7% | -$33.5M |
| Capital Expenditures | $21.1M | $19.9M+3.7% | $19.2M-28.3% | $26.8M-21.4% | $34.1M+140.5% | $14.2M-48.3% | $27.4M+40.3% | $19.5M+554.4% | $3.0M-47.8% | $5.7M-36.0% | $8.9M+54.9% | $5.8M+30.8% | $4.4M+9.9% | $4.0M-11.5% | $4.5M |
| Free Cash Flow | -$26.6M | -$29.7M-694.1% | $5.0M+108.5% | -$58.6M-458.1% | $16.4M-83.2% | $97.2M+3648.0% | -$2.7M-112.2% | $22.4M+297.8% | -$11.3M+84.3% | -$71.9M-2.5% | -$70.1M-8.6% | -$64.5M+1.9% | -$65.8M-27.1% | -$51.8M-36.2% | -$38.0M |
| Investing Cash Flow | -$277.2M | $72.9M+410.3% | -$23.5M+72.6% | -$85.7M-358.5% | $33.2M+117.7% | -$186.9M+36.9% | -$296.1M-419.8% | -$57.0M+37.2% | -$90.7M-3361.6% | $2.8M-73.4% | $10.4M | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $277.3M | -$43.4M-618.3% | $8.4M+103.4% | $4.1M-75.6% | $16.9M-67.5% | $51.9M-83.5% | $314.4M+1199.0% | $24.2M-79.3% | $117.2M+190.2% | $40.4M-22.8% | $52.3M | N/A | N/A | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 | N/A | N/A |
| Share Buybacks | N/A | $0-100.0% | $30.0M | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
TNDM Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 53.8%+1.7pp | 52.1%+2.9pp | 49.2%-2.4pp | 51.5%-2.0pp | 53.5%+1.3pp | 52.2%-1.4pp | 53.6%+4.8pp | 48.9%+7.9pp | 41.0%+13.0pp | 28.0%-8.5pp | 36.5%+5.8pp | 30.7%+9.4pp | 21.3%+75.7pp | -54.5% |
| Operating Margin | -18.4%-7.9pp | -10.5%+20.7pp | -31.2%-19.6pp | -11.6%-14.8pp | 3.2%+4.8pp | -1.6%+3.0pp | -4.6%+19.7pp | -24.3%+34.2pp | -58.5%+34.1pp | -92.6%+2.1pp | -94.7% | -152.2% | -170.4% | -1335.3% |
| Net Margin | -20.2%-10.0pp | -10.2%+19.6pp | -29.8%-18.0pp | -11.8%-14.0pp | 2.2%+9.1pp | -6.9%-0.1pp | -6.8%+59.8pp | -66.7%+1.2pp | -67.9%+31.2pp | -99.1%+0.4pp | -99.4% | -159.9% | -217.7% | -1333.9% |
| Return on Equity | -131.9%-95.4pp | -36.5%+34.5pp | -71.0%-49.5pp | -21.5%-25.1pp | 3.6%+13.0pp | -9.4%+3.3pp | -12.7%+80.7pp | -93.4% | N/A | N/A | -114.1%+31.6pp | -145.7%-91.1pp | -54.6% | N/A |
| Return on Assets | -23.2%-13.3pp | -9.9%+13.5pp | -23.4%-14.4pp | -9.0%-10.7pp | 1.7%+6.5pp | -4.8%+2.8pp | -7.6%+51.9pp | -59.4%+17.2pp | -76.6%-2.3pp | -74.3%-16.2pp | -58.1%+16.6pp | -74.7%-35.8pp | -38.9% | N/A |
| Current Ratio | 2.55-0.4x | 2.93-0.9x | 3.83-1.3x | 5.14-1.0x | 6.150.0x | 6.14+3.4x | 2.78-0.1x | 2.83+1.1x | 1.78-1.1x | 2.93-1.1x | 4.03-1.0x | 5.02-5.2x | 10.21 | N/A |
| Debt-to-Equity | 2.00+0.8x | 1.17+0.3x | 0.91-0.5x | 1.39+0.3x | 1.09+0.1x | 0.96+0.3x | 0.67+0.1x | 0.57 | N/A | N/A | 0.48-0.1x | 0.55+0.1x | 0.40 | N/A |
| FCF Margin | -2.9%-3.5pp | 0.5%+8.4pp | -7.8%-9.9pp | 2.0%-11.8pp | 13.8%+14.4pp | -0.5%-6.7pp | 6.2%+12.3pp | -6.2%+60.6pp | -66.8%+16.4pp | -83.2%+5.4pp | -88.6% | -132.3% | -178.5% | -1535.4% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Tandem Diabetes Ranks
Frequently Asked Questions
What is Tandem Diabetes's annual revenue?
Tandem Diabetes (TNDM) reported $1.0B in total revenue for fiscal year 2025. This represents a 7.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Tandem Diabetes's revenue growing?
Tandem Diabetes (TNDM) revenue grew by 7.9% year-over-year, from $940.2M to $1.0B in fiscal year 2025.
Is Tandem Diabetes profitable?
No, Tandem Diabetes (TNDM) reported a net income of -$204.7M in fiscal year 2025, with a net profit margin of -20.2%.
What is Tandem Diabetes's EBITDA?
Tandem Diabetes (TNDM) had EBITDA of -$169.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Tandem Diabetes have?
As of fiscal year 2025, Tandem Diabetes (TNDM) had $90.6M in cash and equivalents against $310.0M in long-term debt.
What is Tandem Diabetes's gross margin?
Tandem Diabetes (TNDM) had a gross margin of 53.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Tandem Diabetes's operating margin?
Tandem Diabetes (TNDM) had an operating margin of -18.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Tandem Diabetes's net profit margin?
Tandem Diabetes (TNDM) had a net profit margin of -20.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Tandem Diabetes's return on equity (ROE)?
Tandem Diabetes (TNDM) has a return on equity of -131.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Tandem Diabetes's free cash flow?
Tandem Diabetes (TNDM) recorded an outflow of $29.7M in free cash flow during fiscal year 2025. This represents a -694.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Tandem Diabetes's operating cash flow?
Tandem Diabetes (TNDM) recorded an outflow of $9.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Tandem Diabetes's total assets?
Tandem Diabetes (TNDM) had $881.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Tandem Diabetes's capital expenditures?
Tandem Diabetes (TNDM) invested $19.9M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Tandem Diabetes spend on research and development?
Tandem Diabetes (TNDM) invested $193.1M in research and development during fiscal year 2025.
What is Tandem Diabetes's current ratio?
Tandem Diabetes (TNDM) had a current ratio of 2.55 as of fiscal year 2025, which is generally considered healthy.
What is Tandem Diabetes's debt-to-equity ratio?
Tandem Diabetes (TNDM) had a debt-to-equity ratio of 2.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Tandem Diabetes's return on assets (ROA)?
Tandem Diabetes (TNDM) had a return on assets of -23.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Tandem Diabetes's cash runway?
Based on fiscal year 2025 data, Tandem Diabetes (TNDM) had $90.6M in cash against an annual operating cash burn of $9.7M. This gives an estimated cash runway of approximately 112 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Tandem Diabetes's Altman Z-Score?
Tandem Diabetes (TNDM) has an Altman Z-Score of 0.34, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Tandem Diabetes's Piotroski F-Score?
Tandem Diabetes (TNDM) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Tandem Diabetes's earnings high quality?
Tandem Diabetes (TNDM) reported a net loss of $204.7M while operations used $9.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Tandem Diabetes cover its interest payments?
Tandem Diabetes (TNDM) reported an operating loss of $187.3M against $7.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Tandem Diabetes?
Tandem Diabetes (TNDM) scores 41 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.